ACAD - ACADIA Pharmaceuticals Inc Stock Price, Fair Value and News

16.70USD+0.39 (+2.39%)Market Closed

Market Summary

USD16.70+0.39

Market Closed

2.39%

ACAD Alerts

1 major insider sales recently.

ACAD Stock Price

View Fullscreen

ACAD RSI Chart

ACAD Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-44.9

Price/Sales (Trailing)

3.79

EV/EBITDA

-51.7

Price/Free Cashflow

165.25

ACAD Price/Sales (Trailing)

ACAD Profitability

EBT Margin

-7.03%

Return on Equity

-14.19%

Return on Assets

-8.18%

Free Cashflow Yield

0.61%

ACAD Fundamentals

ACAD Revenue

Revenue (TTM)

726.4M

Rev. Growth (Yr)

69.27%

Rev. Growth (Qtr)

9.14%

ACAD Earnings

Earnings (TTM)

-61.3M

Earnings Growth (Yr)

209.76%

Earnings Growth (Qtr)

170.27%

Breaking Down ACAD Revenue

Last 7 days

-0.7%

Last 30 days

-8.2%

Last 90 days

-38.0%

Trailing 12 Months

-18.5%

How does ACAD drawdown profile look like?

ACAD Financial Health

Current Ratio

2.42

ACAD Investor Care

Shares Dilution (1Y)

1.57%

Diluted EPS (TTM)

-0.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	520.2M	550.9M	631.9M	726.4M
2022	493.1M	512.4M	511.5M	517.2M
2021	458.2M	463.4M	474.4M	484.1M
2020	366.2M	393.1M	419.1M	441.8M
2019	237.9M	264.0M	300.3M	339.1M
2018	158.5M	185.1M	207.8M	223.8M
2017	40.2M	63.0M	93.3M	124.9M
2016	4.4M	8.7M	13.0M	17.3M
2015	0	0	129.0K	118.0K
2014	758.0K	335.0K	110.0K	120.0K
2013	4.9M	4.7M	1.5M	1.1M
2012	2.1M	2.2M	5.1M	4.9M
2011	32.1M	22.1M	12.1M	2.1M
2010	0	18.3M	30.2M	42.1M
2009	0	0	0	6.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of ACADIA Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	teehan brendan	sold	-45,890	17.87	-2,568	evp, coo, head of commercial
Apr 08, 2024	kihara james	sold	-31,987	17.87	-1,790	principal accounting officer
Apr 08, 2024	davis stephen	sold	-474,877	17.87	-26,574	ceo
Apr 08, 2024	schneyer mark c.	sold	-48,534	17.87	-2,716	evp, chief financial officer
Apr 07, 2024	kihara james	acquired	-	-	1,489	principal accounting officer
Apr 05, 2024	davis stephen	acquired	-	-	51,999	ceo
Apr 05, 2024	schneyer mark c.	acquired	-	-	5,275	evp, chief financial officer
Apr 05, 2024	kihara james	acquired	-	-	2,010	principal accounting officer
Apr 05, 2024	teehan brendan	acquired	-	-	5,024	evp, coo, head of commercial
Mar 27, 2024	davis stephen	sold	-317,081	17.9	-17,714	ceo

Which funds bought or sold ACAD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	NATIXIS ADVISORS, L.P.	reduced	-56.38	-949,000	330,000	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-1,167	1,683	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-8.69	-7,947,620	9,301,450	-%
Apr 25, 2024	Lindbrook Capital, LLC	added	1.83	-1,361	2,052	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	added	2.5	-289,236	443,575	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-4.95	-830,000	1,060,000	-%
Apr 25, 2024	WCM INVESTMENT MANAGEMENT, LLC	new	-	5,214,830	5,214,830	0.01%
Apr 24, 2024	DekaBank Deutsche Girozentrale	added	2.89	-1,180,000	1,745,000	-%
Apr 24, 2024	PSI Advisors, LLC	unchanged	-	-7,692	11,094	-%
Apr 24, 2024	CENTRAL TRUST Co	unchanged	-	-641	925	-%

Are Funds Buying or Selling ACAD?

Are funds buying ACAD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACAD

No. of Funds

ACAD Alerts

1 major insider sales recently.

Unveiling ACADIA Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rtw investments, lp	6.9%	11,253,551	SC 13G
Feb 13, 2024	vanguard group inc	8.16%	13,396,009	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	6.9%	11,409,218	SC 13G/A
May 24, 2023	baker bros. advisors lp	26.5%	43,084,280	SC 13D/A
Feb 14, 2023	price t rowe associates inc /md/	2.6%	4,279,254	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.20%	13,279,775	SC 13G/A
Feb 01, 2023	blackrock inc.	6.3%	10,258,738	SC 13G/A
Jan 17, 2023	baker bros. advisors lp	26.0%	42,163,470	SC 13D/A

Recent SEC filings of ACADIA Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 15, 2024	3	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading

Peers (Alternatives to ACADIA Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.3B	2.4B	-8.70%	-12.49%	91.05	6.31	15.42%	18.43%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

ACADIA Pharmaceuticals Inc News

Latest updates

ACADIA Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	9.1%	231,041,000	211,699,000	165,235,000	118,462,000	136,490,000	130,714,000	134,563,000	115,468,000	130,758,000	131,612,000	115,221,000	106,554,000	121,007,000	120,577,000	110,103,000	90,068,000	98,326,000	94,586,000	83,205,000	62,959,000	59,571,000
Costs and Expenses	-27.2%	196,097,000	269,475,000	162,198,000	172,046,000	182,553,000	161,580,000	168,214,000	228,484,000	175,415,000	146,913,000	158,930,000	173,326,000	188,169,000	206,476,000	154,113,000	179,583,000	154,725,000	140,007,000	140,296,000	150,593,000	126,846,000
S&GA Expenses	13.9%	111,465,500	97,890,000	95,968,000	101,235,000	104,402,000	78,108,000	89,901,000	96,679,000	105,912,000	81,666,000	96,789,000	111,661,000	120,752,000	81,592,000	84,344,000	101,973,000	91,871,000	72,696,000	67,981,000	93,090,000	74,271,000
R&D Expenses	-57.5%	66,741,000	156,963,000	58,771,000	69,144,000	75,738,000	81,336,000	75,646,000	128,855,000	66,942,000	58,565,000	56,935,000	56,973,000	62,116,000	120,083,000	64,295,000	72,636,000	57,520,000	62,622,000	67,320,000	52,923,000	48,183,000
EBITDA Margin	66.8%	-0.07	-0.21	-0.19	-0.28	-0.41	-0.42	-0.39	-0.43	-0.34	-0.40	-0.56	-0.56	-	-	-	-	-	-	-	-	-
Income Taxes	-146.6%	-6,079,500	13,033,000	5,200,000	-1,918,000	809,500	800,000	443,000	500,000	189,000	-332,000	473,000	21,000	417,000	-199,000	393,000	-	400,000	-264,000	365,000	375,000	14,000
Earnings Before Taxes	176.1%	39,662,000	-52,100,000	6,343,000	-44,939,000	-40,859,500	-26,415,000	-33,600,000	-112,600,000	-42,905,000	-14,789,000	-43,398,000	-66,427,000	-66,343,000	-84,859,000	-41,748,000	-88,023,000	-52,636,000	-42,242,000	-54,576,000	-84,929,000	-65,478,000
EBT Margin	66.3%	-0.07	-0.21	-0.19	-0.28	-0.41	-0.42	-0.40	-0.43	-0.35	-0.40	-0.56	-0.57	-	-	-	-	-	-	-	-	-
Net Income	170.3%	45,797,000	-65,176,000	1,114,000	-43,021,000	-41,725,000	-27,183,000	-34,011,000	-113,056,000	-43,094,000	-14,457,000	-43,871,000	-66,448,000	-66,760,000	-84,660,000	-42,141,000	-88,023,000	-53,036,000	-41,978,000	-54,941,000	-85,304,000	-65,492,000
Net Income Margin	64.2%	-0.08	-0.24	-0.20	-0.28	-0.42	-0.42	-0.40	-0.43	-0.35	-0.40	-0.56	-0.57	-	-	-	-	-	-	-	-	-
Free Cashflow	-	85,389,000	-	8,201,000	-17,933,000	-23,854,000	-727,000	-13,125,000	-76,329,000	-23,121,000	-17,064,000	-25,372,000	-61,225,000	-29,487,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	18.4%	749	633	643	655	588	602	613	624	700	718	724	755	783	796	760	747	783	766	461	501	540
Current Assets	23.4%	616	499	493	503	508	522	533	542	618	641	646	674	718	730	736	724	760	742	437	476	526
Cash Equivalents	92.1%	189	98.00	108	291	115	155	140	205	147	95.00	267	304	326	452	310	173	190	385	74.00	98.00	135
Inventory	-	-	-	-	-	-	-	-	-	-	14.00	11.00	10.00	10.00	8.00	6.00	6.00	6.00	5.00	4.00	5.00	4.00
Net PPE	-5.6%	5.00	5.00	5.00	6.00	6.00	7.00	7.00	8.00	8.00	9.00	9.00	10.00	9.00	8.00	7.00	5.00	3.00	3.00	3.00	4.00	3.00
Liabilities	17.3%	317	270	247	281	187	177	178	179	159	151	160	174	156	141	97.00	109	84.00	76.00	72.00	83.00	61.00
Current Liabilities	21.3%	254	210	188	224	126	117	118	120	96.00	88.00	95.00	109	106	92.00	86.00	100	75.00	68.00	64.00	75.00	60.00
Shareholder's Equity	19.2%	432	362	396	374	400	426	435	445	541	567	565	582	627	655	663	638	699	689	389	418	479
Retained Earnings	1.8%	-2,430	-2,476	-2,411	-2,412	-2,369	-2,327	-2,300	-2,266	-2,153	-2,110	-2,096	-2,052	-1,985	-1,918	-1,834	-1,792	-1,704	-1,651	-1,609	-1,554	-1,468
Additional Paid-In Capital	0.8%	2,863	2,839	2,808	2,787	2,771	2,755	2,736	2,712	2,695	2,677	2,661	2,634	2,613	2,573	2,496	2,429	2,403	2,340	1,997	1,972	1,948
Shares Outstanding	0.4%	165	164	163	162	162	162	162	161	161	161	161	160	-	-	-	-	-	-	-	-	-
Float	-	-	-	2,900	-	-	-	1,700	-	-	-	2,500	-	-	-	4,600	-	-	-	2,200	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	244.8%	85,389	-58,955	8,201	-17,933	-23,854	-727	-13,125	-76,329	-23,120	-17,064	-25,327	-60,149	-27,488	-22,793	-36,883	-49,002	-29,707	-18,851	-38,397	-64,175	-39,079
Share Based Compensation	-2.8%	18,023	18,539	15,154	14,705	14,414	18,312	20,512	14,963	12,880	15,546	22,005	13,184	21,195	21,372	19,507	22,348	19,850	22,023	20,422	19,883	20,401
Cashflow From Investing	-101.0%	-347	34,110	-194,283	192,518	-17,748	15,441	-55,797	131,345	71,549	-156,321	-17,207	30,877	-116,958	152,994	126,865	29,608	-209,144	9,923	10,627	22,758	-188,949
Cashflow From Financing	-57.4%	5,434	12,751	5,478	1,466	1,614	287	3,831	2,467	4,365	1,066	5,005	7,726	18,126	11,715	47,401	3,754	43,058	319,967	4,646	4,176	300,603

ACAD Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Revenues

Type of Revenue [Extensible List]

us-gaap:ProductMember

Total revenues

$ 726,437

$ 517,235

$ 484,145

Operating expenses

Type of Cost, Good or Service [Extensible List]

us-gaap:ProductMember

Cost of product sales

$ 41,638

$ 10,166

$ 19,141

Research and development

351,619

361,575

239,415

Selling, general and administrative

406,559

369,090

396,028

Total operating expenses

799,816

740,831

654,584

Loss from operations

(73,379)

(223,596)

(170,439)

Interest income, net

17,234

6,610

591

Other income

5,109

3,542

2,329

Loss before income taxes

(51,036)

(213,444)

(167,519)

Income tax expense

10,250

2,531

351

Net loss

$ (61,286)

$ (215,975)

$ (167,870)

Net loss per common share, basic

$ (0.37)

^[1]

$ (1.34)

^[1]

$ (1.05)

Net loss per common share, diluted

$ (0.37)

^[1]

$ (1.34)

^[1]

$ (1.05)

Weighted average common shares outstanding, basic

163,819

161,683

160,493

Weighted average common shares outstanding, diluted

163,819

161,683

160,493

[1]	Basic and diluted net income (loss) per common share are computed independently for each quarter and the full year based upon respective average shares outstanding. Therefore, the sum of the quarterly net income (loss) per common share amounts may not equal the annual amounts reported.

ACAD Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 188,657	$ 114,846
Investment securities, available-for-sale	250,208	301,977
Accounts receivable, net	98,267	62,195
Interest and other receivables	4,083	885
Inventory	35,819	6,636
Prepaid expenses	39,091	21,398
Total current assets	616,125	507,937
Property and equipment, net	4,612	6,021
Operating lease right-of-use assets	51,855	55,573
Intangible assets, net	65,490	0
Restricted cash	5,770	5,770
Long-term inventory	4,628	4,924
Other assets	476	7,587
Total assets	748,956	587,812
Liabilities and stockholders’ equity
Accounts payable	17,543	12,746
Accrued liabilities	236,711	112,884
Total current liabilities	254,254	125,630
Operating lease liabilities	47,800	52,695
Other long-term liabilities	15,147	9,074
Total liabilities	317,201	187,399
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022	0	0
Common stock, $0.0001 par value; 225,000,000 shares authorized at December 31, 2023 and 2022; 164,650,219 shares and 162,064,872 shares issued and outstanding at December 31, 2023 and 2022, respectively	16	16
Additional paid-in capital	2,862,552	2,770,923
Accumulated deficit	(2,430,837)	(2,369,551)
Accumulated other comprehensive income (loss)	24	(975)
Total stockholders’ equity	431,755	400,413
Total liabilities and stockholders’ equity	$ 748,956	$ 587,812

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.

CEO	Mr. Stephen R. Davis J.D.
WEBSITE	https://acadia.com
INDUSTRY	Biotechnology
EMPLOYEES	540

ACADIA Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for ACADIA Pharmaceuticals Inc? What does ACAD stand for in stocks?

ACAD is the stock ticker symbol of ACADIA Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ACADIA Pharmaceuticals Inc (ACAD)?

As of Fri Apr 26 2024, market cap of ACADIA Pharmaceuticals Inc is 2.75 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACAD stock?

You can check ACAD's fair value in chart for subscribers.

What is the fair value of ACAD stock?

You can check ACAD's fair value in chart for subscribers. The fair value of ACADIA Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ACADIA Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACAD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ACADIA Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ACAD is over valued or under valued. Whether ACADIA Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ACADIA Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACAD.

What is ACADIA Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, ACAD's PE ratio (Price to Earnings) is -44.9 and Price to Sales (PS) ratio is 3.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACAD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ACADIA Pharmaceuticals Inc's stock?

In the past 10 years, ACADIA Pharmaceuticals Inc has provided -0.017 (multiply by 100 for percentage) rate of return.